报价延迟最少15分钟:2026/04/25 18:44 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.24 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.43/-0.82
|
|
企业价值
105.67M
|
| 资产负债 |
|
每股账面净值
2.93
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.08
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novelintegrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform. |
